PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
Visit https://www.peervoice.com/RTV860 to view the entire programme with slides. After completing “Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations”, participants will be able to: Compare current and emerging fibroblast growth factor receptor (FGFR) inhibitors based on pharmacology, study designs and outcomes, and place in therapy; Identify specific patient-level characteristics, comorbidities, and presentations which may impact treatment selection in cholangiocarcinoma (CCA); and Design individualised regimens for specific patients with CCA and FGFR alterations.